Emerald Advisers and F/m Investments Announce the Launch of the F/m Emerald Life Sciences Innovation ETF (LFSC)
Actively Managed ETF Provides Investors Targeted Exposure to Leading Life Sciences Innovations in Biotechnology, Pharmaceuticals, and Medical Devices
“We are excited to bring this ETF to market, offering investors access to some of the most cutting-edge developments in healthcare and biotechnology,” shared Stacey Sears, Senior Vice President & Portfolio Manager at Emerald. “We say “innovation starts small,” as small-cap companies are often first-movers, particularly in sectors like gene therapies and medical diagnostics, where they can be nimble and groundbreaking. Emerald’s proprietary research-driven process focuses on identifying these high-potential firms early, leveraging our sector-specific investment team to capture the most promising life sciences opportunities, positioning the fund for potential long-term growth.”
The F/m Emerald Life Sciences Innovation ETF is actively managed, focusing on small and mid-cap companies who we believe are poised to break through in biotechnology, pharmaceuticals, and medical technology. This sector is particularly compelling as emerging biopharma companies accounted for two-thirds of clinical trial starts in 2023, and
Speaking on LFSC, Alexander Morris, CEO of F/m Investments, shared, "The F/m Emerald Life Sciences Innovation ETF provides an opportunity for investors to tap into the transformative advancements taking place in healthcare and biotech. We’re proud to partner with Emerald to offer investors access to the dynamic growth potential of this crucial sector and look forward to developing additional products in the future to meet investors’ needs."
The life sciences industry is experiencing rapid growth, fueled by an aging population, increasing healthcare demand, and accelerated investments in biotechnology and medical innovation. With
"Emerald has a long history of identifying high-growth opportunities in emerging sectors. The launch of LFSC reflects our commitment to delivering innovative investment solutions that align with long-term growth trends,” said Scott Rehr, CEO of Emerald. “As we explored entering the active ETF space, it was crucial to find a partner with a proven history in ETF governance who understands the complexities involved. That’s why we chose to partner with The RBB Fund Complex. This partnership enables us to bring a new and innovative ETF to market backed by both Emerald’s rigorous research process and RBB’s operational experience.”
In conjunction with the launch of the LFSC, Emerald has released a comprehensive white paper outlining the unprecedented growth opportunities within the life sciences sector. The paper highlights key trends, including how
About Emerald Advisers
Emerald Advisers, LLC is an asset management firm providing research-based portfolio management. Emerald and its subsidiaries provide growth-oriented portfolios for institutions and individuals. Founded in 1991, Emerald provides active
About F/m Investments
F/m Investments is a
About The RBB Fund Complex
The RBB Fund, Inc. and The RBB Fund Trust, together, are a turnkey ETF and mutual fund solution that permits an investment adviser to focus on asset management and distribution, while RBB facilitates the establishment, servicing, and governance of funds. RBB oversees approximately
An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus, which contains this and other information about the fund, may be obtained by calling 1-800-617-0004/visiting www.emeraldetfs.com. The prospectus should be read carefully before investing.
ETFs are subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of an ETF’s shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.
The F/m Emerald Life Sciences Innovation ETF is distributed by Quasar Distributors, LLC.
Investing involves risk. Principal loss is possible. The Fund focuses its investments in securities of companies that are categorized in the “life sciences” sector, including companies in the pharmaceutical, biotechnology, health care services, and medical device industries. Because of this, companies in the Fund's portfolio may share common characteristics and may be more sensitive to changes in government funding or subsidies, new or anticipated legislative changes, or technological advances. To the extent the Fund focuses on the health care sector, the Fund may be more susceptible to the particular risks that may affect companies in the health care sector than if it were invested in a wider variety of companies in unrelated sectors. Investments in securities of micro- and small-capitalization companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of larger-capitalization companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031854707/en/
Emerald Advisers, LLC
3175 Oregon Pike
717.556.8900
800.722.4123
www.TeamEmerald.com
Media Contacts:
Emerald
Matt Yemma
Lyceus Group
Myemma@lyceusgroup.com
909-633-9396
F/m Investments
Tucker Slosburg
Lyceus Group
fmpr@lyceusgroup.com
206-635-4196
The RBB Fund Complex
Rex Carlin
Red Mountain Media
rex@redmtnmedia.com
206-240-5108
Source: Emerald Advisers
